Medi Caps Ltd
Incorporated in 1983, Medi-Caps Ltd is in the business of real estate and pharmaceuticals[1]
- Market Cap ₹ 29.9 Cr.
- Current Price ₹ 24.0
- High / Low ₹ 47.2 / 21.0
- Stock P/E 33.6
- Book Value ₹ 54.3
- Dividend Yield 0.00 %
- ROCE -0.13 %
- ROE 0.27 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.44 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 1.80% over last 3 years.
- Company has high debtors of 552 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.37 | 27.37 | 25.04 | 22.76 | 26.38 | 25.28 | 10.91 | 0.00 | 0.00 | 0.10 | 7.17 | 2.42 | 2.66 | |
| 24.21 | 25.52 | 23.42 | 21.99 | 25.93 | 25.32 | 19.97 | 0.00 | 0.56 | 0.39 | 2.33 | 2.53 | 2.62 | |
| Operating Profit | 3.16 | 1.85 | 1.62 | 0.77 | 0.45 | -0.04 | -9.06 | 0.00 | -0.56 | -0.29 | 4.84 | -0.11 | 0.04 |
| OPM % | 11.55% | 6.76% | 6.47% | 3.38% | 1.71% | -0.16% | -83.04% | -290.00% | 67.50% | -4.55% | 1.50% | ||
| -1.57 | 1.21 | 0.46 | 1.13 | 0.67 | 1.14 | 1.11 | -0.12 | 0.64 | 0.53 | 0.15 | 0.56 | 0.76 | |
| Interest | 0.03 | 0.01 | 0.01 | 0.02 | 0.02 | 0.04 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.34 | 0.32 | 0.33 | 0.37 | 0.34 | 0.35 | 0.36 | 0.00 | 0.09 | 0.09 | 0.16 | 0.16 | 0.16 |
| Profit before tax | 1.22 | 2.73 | 1.74 | 1.51 | 0.76 | 0.71 | -8.32 | -0.12 | -0.02 | 0.15 | 4.83 | 0.29 | 0.64 |
| Tax % | 89.34% | 29.30% | 32.18% | 23.18% | 26.32% | 16.90% | 0.12% | -8.33% | 50.00% | 0.00% | 19.46% | -93.10% | |
| 0.14 | 1.94 | 1.18 | 1.16 | 0.56 | 0.59 | -8.33 | -0.11 | -0.04 | 0.15 | 3.89 | 0.56 | 0.89 | |
| EPS in Rs | 0.11 | 1.56 | 0.95 | 0.93 | 0.45 | 0.47 | -6.68 | -0.09 | -0.03 | 0.12 | 3.12 | 0.45 | 0.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -26% |
| 3 Years: | % |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -21% |
| 5 Years: | 15% |
| 3 Years: | 33% |
| TTM: | 75% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -9% |
| 3 Years: | -12% |
| 1 Year: | -46% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | 2% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 | 12.47 |
| Reserves | 49.95 | 51.89 | 53.07 | 53.90 | 54.45 | 55.04 | 47.38 | 48.50 | 48.82 | 48.64 | 54.02 | 54.87 | 55.19 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.12 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 4.93 | 4.58 | 5.47 | 5.64 | 4.73 | 6.16 | 1.65 | 1.66 | 0.52 | 0.52 | 1.60 | 0.68 | 0.63 | |
| Total Liabilities | 67.35 | 68.94 | 71.01 | 72.01 | 71.82 | 73.79 | 61.56 | 62.63 | 61.81 | 61.63 | 68.09 | 68.02 | 68.29 |
| 3.90 | 3.96 | 3.64 | 4.96 | 5.01 | 4.99 | 3.63 | 3.26 | 2.78 | 2.46 | 3.34 | 3.18 | 2.27 | |
| CWIP | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.08 |
| Investments | 41.75 | 48.25 | 49.56 | 49.29 | 49.81 | 50.67 | 52.15 | 54.39 | 53.68 | 51.98 | 54.03 | 55.81 | 57.70 |
| 21.60 | 16.73 | 17.81 | 17.76 | 17.00 | 18.13 | 5.78 | 4.98 | 5.35 | 7.19 | 10.72 | 8.95 | 8.24 | |
| Total Assets | 67.35 | 68.94 | 71.01 | 72.01 | 71.82 | 73.79 | 61.56 | 62.63 | 61.81 | 61.63 | 68.09 | 68.02 | 68.29 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.57 | 6.88 | 1.44 | 2.70 | 0.86 | 1.33 | -0.92 | 2.24 | -0.95 | -2.60 | 3.09 | 1.85 | |
| 1.61 | -6.78 | -1.31 | -1.76 | -0.96 | -1.19 | -0.40 | -2.19 | 1.01 | 1.85 | -3.09 | -1.85 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | -0.05 | -0.06 | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.04 | 0.10 | 0.13 | 0.94 | 0.07 | 0.09 | -1.38 | -0.02 | 0.06 | -0.75 | 0.00 | 0.01 |
| Free Cash Flow | -1.64 | 6.59 | 1.44 | 2.09 | 0.46 | 1.00 | -0.92 | 2.28 | -0.65 | -2.45 | 3.13 | 1.78 |
| CFO/OP | -18% | 412% | 122% | 394% | 231% | -3,575% | 10% | 170% | 897% | 83% | -1,445% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106.69 | 88.55 | 96.35 | 97.18 | 96.02 | 90.24 | 88.99 | 8,176.00 | 236.72 | 552.02 | ||
| Inventory Days | 169.28 | 194.04 | 248.47 | 281.91 | 219.00 | 266.47 | 20.89 | 1,825.00 | ||||
| Days Payable | 36.41 | 33.53 | 60.03 | 83.09 | 55.89 | 118.09 | 16.56 | 1,095.00 | ||||
| Cash Conversion Cycle | 239.55 | 249.06 | 284.79 | 296.00 | 259.13 | 238.62 | 93.33 | 8,176.00 | 236.72 | 552.02 | ||
| Working Capital Days | 153.09 | 158.96 | 175.94 | 179.45 | 156.90 | 159.25 | 131.81 | 25,623.00 | 481.07 | 1,297.11 | ||
| ROCE % | 1.94% | 4.29% | 2.69% | 1.52% | 1.14% | 0.77% | -13.56% | 0.00% | -0.85% | -0.62% | 7.34% | -0.13% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Export Earnings (Foreign Exchange Inflow) INR Lakhs |
|
||||||
| Number of Permanent Employees (Standalone) Number |
|||||||
| Hard Gelatin Capsule Production Volume (Parent Company) Lakhs |
|||||||
| Hard Gelatin Capsules Sold (Parent Company) Lakhs |
|||||||
| Number of Manufacturing Plants (Parent Company) Number |
|||||||
| Average Selling Price - Hard Gelatin Capsules INR per 1000 capsules |
|||||||
| Real Estate Project Sales (Medicaps Business Park) Percentage Sold |
|||||||
Documents
Announcements
- Closure of Trading Window 25 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Extract of un-audited standalone and consolidated financial results of the company for the quarter and nine month ended on 31.12.2025 published in Free press journal …
- Unaudited Standalone & Consolidated Financial Results For The Quarter & Nine Month Ended 31.12.2025 11 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Dated 11.02.2026
11 Feb - Unaudited standalone and consolidated Q3/nine-month results approved for period ended 31 Dec 2025; limited review unmodified and to be uploaded online.
-
Board Meeting Intimation for (Serial No. 04/2025-26) Of The Company, Scheduled To Be Held On Wednesday, 11Th Day Of February, 2026 Pursuant To Regulation 29 Of SEBI (LODR) Regulations, 2015.
4 Feb - Board meets Feb 11, 2026 to approve unaudited Q3/9M FY2025-26 results; trading window opens 48 hours after.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
MCL operates in real estate as a parent company and pharma division through its wholly owned subsidiary. The company entered the real estate segment for city centric developments by way of Land acquisition and developing premium residential and commercial properties. It has almost completed its first project Medicaps Business Park and also sold ~50% of shops in the project